{"name":"Sebela Pharmaceuticals Development LLC","slug":"sebela-pharmaceuticals-development-llc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"ECP Colon Prep Kit","genericName":"ECP Colon Prep Kit","slug":"ecp-colon-prep-kit","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"ECP Colon Prep Kit","genericName":"ECP Colon Prep Kit","slug":"ecp-colon-prep-kit","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxPU1FMMG5EMlVhaTd5N2g5cEs0MDRSZG9hUXhPVF9iV2E2am9wRmdNcGpENmRVRm1VZWFIb1dMaURuZWdOOV9FTFo1VHRJcGZsdUM5M1NGenRlSDhJRHYycndBN2dfcXR6cm92a09BWTFsS3N0elFzUXFYbXZnWUg0S3F1d3JwVGh6T2FTZDBobm81ZjNHUzc2Z2NyMDY0T1hxQ0hIeXd3?oc=5","date":"2026-02-24","type":"pipeline","source":"Fierce Biotech","summary":"Organon pays $27.5M upfront for Sebela's hormone-free copper IUD - Fierce Biotech","headline":"Organon pays $27.5M upfront for Sebela's hormone-free copper IUD","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAJBVV95cUxQOTU2QlhjTTlGVHNzR250S2lJY0t5bG54aGpWNXlXblpkaS1tazVPcGZwNGt4UkNZR1gwT0g4TVk5MWxNdzZGbHl4TEZfdE9iWTlxNTZCbnIzaDAtaFJweWxzT3F0bVh2ZDlLdFluWjZSS0tYVHcyZUxWQk53NUpydTRaSDNPbTRvVElubjNKZHphRmVHZUYxRmpPdlNNNnhlZEZLMHFneE10em0zZ1NtblhFbFkxY28wVkZFVTJCX2Z2TE5CejFfekNzSm5SQXRTZ2RpU0dKV2ZueWdnTjFYWUpaOUhGNFBmNnRwVW1yTmRSV2VtRmVhYlpUSjR6T1B0OGs5a0hpUDVDZ2ZjNzBmcWFNVkl3VGRMcWdaTkJjZjFHVFp2?oc=5","date":"2026-01-12","type":"regulatory","source":"PR Newswire","summary":"Sebela Pharmaceuticals® Announces Submission of New Drug Application to FDA for Tegoprazan for the Treatment of Gastroesophageal Reflux Disease - PR Newswire","headline":"Sebela Pharmaceuticals® Announces Submission of New Drug Application to FDA for Tegoprazan for the Treatment of Gastroes","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgJBVV95cUxPc0ROWTY0R2RqLUhIeUIwM19NQWFkaFVKMUFuR0VCU2JiSEdyaDdieDRqNERGT3lsWjg0OUY5Z3pLX1BCMHNmNFFubUpjODJxTHpkUFJjeEIyZ0hiU3lrNUloaGFMNGlzZ3ZPS1BfT2FBNWwxUWpycHRHdDNXOFRhcXRzdk5sX3NtQ3d2TmlOd2NFRy1renlMZFU3Wk1UZGNzOG5VZEstZ1YxRGh4bzJNUW1ERUNRejNWdTZmVHdRbzlzcjlodGh6SFQ2TWNfcmtUMjlvTGg5UmNfR0haNEtlN1ByOXlEZ1N0eDcxUG1lemY3bXpUalIxLTVvRXdFREhSUkFCZkI5YThXNFNvbTAxTkR3?oc=5","date":"2025-11-17","type":"pipeline","source":"GlobeNewswire","summary":"Azurity Pharmaceuticals and Sebela Pharmaceuticals Announce the Sale of Sebela’s Bowel Prep Franchise to Azurity - GlobeNewswire","headline":"Azurity Pharmaceuticals and Sebela Pharmaceuticals Announce the Sale of Sebela’s Bowel Prep Franchise to Azurity","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAJBVV95cUxORU1PZ1VweTN4dmJhLXQyTm9VSldjU3hIRlRkMFc5TkZBTUJxUFVxRWxpOVFPWUNKTEp1VnhLTVNta1U1NXNsUlhSOVROd2R3Z0dDYWxBcjIzNENrNl9kWVFpZWpBM2dfd2Znd2VSeXkybzFQNWFZbEdydDNLTTA5Qkk2SzlzVjZPYXNEOVVnQTlCZlNzWnpSajI1eGFzUm1RVjhNZ0xfc3gzR3JOMUJobTZoSDlPd2pCZUhEekotbFItcDllX3FoY3E5d3NtSE4wSVExWk8wM1k3dldia1BSOTdjbHJiWnM0azdtN2NsTm1kWTBLb3BJMWlNd3EwV05nYWZlQkZia3FHdzBqcGFzOTROeE1lc1dvN3NST1ZtR3hSbkhWV3RFa1UzSUlJa01y?oc=5","date":"2025-08-07","type":"trial","source":"PR Newswire","summary":"Sebela Pharmaceuticals® Announces Successful Completion of Phase 3 TRIUMpH Program of Tegoprazan in GERD with Positive 24-Week Maintenance Phase Results - PR Newswire","headline":"Sebela Pharmaceuticals® Announces Successful Completion of Phase 3 TRIUMpH Program of Tegoprazan in GERD with Positive 2","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi9wFBVV95cUxPd2tidDEtT1pOd05qWW94ZndJbjJBYTBCR2ZlMVNPZFdOS216cjN2WngxcEhzTTBEZ2lYRGtrcGlqQlFhWlNNMjhTRl9TbE8yQ2I3bHU5enR1eDF2eUJvVktsaGwxUXlIX3UzUThOb0RiZ19lbnY1X1V6YVRpNnoyX1dOUEhCOFplTmJfZW9WUmFJSkRsek00RXA5X20wdE9JVGFuempFdWVaTktzUkpkZDVxc0kteFZRdjNlWGkwNUVNLUpGX3Z0aFlpWnI4S2FhS3NVTzFrTDNKTXlpWTR6RDVqZFB0TGlmUkpmb1dvb2xVd0pZVHh3?oc=5","date":"2025-04-23","type":"trial","source":"PR Newswire","summary":"Sebela Pharmaceuticals® Announces Positive Topline Results from Phase 3 TRIUMpH Program of Tegoprazan in GERD - PR Newswire","headline":"Sebela Pharmaceuticals® Announces Positive Topline Results from Phase 3 TRIUMpH Program of Tegoprazan in GERD","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxNQVU0NFBzMEdCZDhEdlZ2R2JuU0hBZWtDNUtIaHBMbkVfdnlvbFRFM1ZwdWJVRFFJLUNSdWZOODl6aVVzTkExSGt4Zmt0VkxFZEFTZkhhU2dfU2NyMjRXMWVhV1gycGktTDZDbFJLNGNobVNGejZ2bkNtV0pMQlNMTkFUUDVGWlg5WF9sc05TcE8?oc=5","date":"2023-02-24","type":"trial","source":"Fierce Biotech","summary":"Destiny seals C. diff therapy's phase 3 fate with Sebela - Fierce Biotech","headline":"Destiny seals C. diff therapy's phase 3 fate with Sebela","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiyAFBVV95cUxQQVNVdU10X2ZCVmRfR0FHN2tleVVqZzJlS2UxRldPOVNZTS1wbWNNUkNORURaUi0yMl9OTUw3ZU5FWlh2Zy1rZXZUQ3R1WHl5VnV0M0hLM3FiWEpoQmRLV2E5ZEhMMUlDNEVDZmp2d0RnMmpzUEZWelp3THRmYmJjV3AwQ25JQTcxVVZfdHg1Y0dYM3gxM3Q0MmE2ZE15M3dvQ2x6cG56VVZBcE4zX1NXQnRORkl1aW55WXVpQi1sZUh4SjhtRk45aA?oc=5","date":"2022-10-24","type":"pipeline","source":"PR Newswire","summary":"Sebela Pharmaceuticals® Appoints Victor Parker as Chief Commercial Officer - PR Newswire","headline":"Sebela Pharmaceuticals® Appoints Victor Parker as Chief Commercial Officer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0wJBVV95cUxOV0dPT0kybXhHakdvaVJ6YU1tMXFUcE1tUVM3OXhOV0NseWd4cUxCNlRKQkRaYWNnZ2xOckJIaWx3djhUMmprNmNYU2Y2RVlpV25Uakl1bWVqbkhScXFDRW9Rcjl3dU51a2ZaaEZ0YTFHRFdXQ21hc2doUXVqNmV1Wlp2RnRYMjU2RVBndHlYV2RGaVJMRllmQkh1d0VHNmRoVndORjFPLUdMNVRHdVVTN3JOZHJ6eHFNSHpDTGtFX19tbmhaUW44ZUt3eUJFb3FxeTNONU9mWWdHZkhBNTRCUDN2MFFId3FfdTdZOHFwV1VJZURUNGt1RTZaSWdENGQxcUx4Y3FRUmNldnBKbHpBZ3Z0TmpySDE1T3N1UHRZVUd3dmQ2NmtjeEJhQXlEbGFTbGdlUnl2dWktUXduZFlQaUxSenhPaml4bGNqZTN5T0dOYzg?oc=5","date":"2021-03-23","type":"deal","source":"PR Newswire","summary":"CellMax Life and Sebela Pharmaceuticals Enter Strategic Development and Commercialization Partnership for FirstSight™ Blood Test for Detection of Colorectal Cancer and Pre-Cancer - PR Newswire","headline":"CellMax Life and Sebela Pharmaceuticals Enter Strategic Development and Commercialization Partnership for FirstSight™ Bl","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3wFBVV95cUxPSDZxbVdHa1I4RXhOOWVhYnExYlZnc0JzRDhBNE90RmlacUZIdlJsMTdheXBHYm1VeUdNN1IwMm9INXpqU3hCYUhOVXJ4VlUzcU9Wbk5ybTRtOEEtYmkwN0xWdk9VVTJxeGltZWhsODVBdmd3WkpCbkZkay1rbnIzUGdRUWNCNUc2TTZfUm1Ea2JEMnh2SXFDazBzMUJDUnBKZWVxUE9aaXhhdWk1ZzZreDAxSVdiMkgxOXdoUTYwVU5oNHFDN3h3VHRaTkJmeld0MmhLdFEtZnVjdFVLaGh3?oc=5","date":"2020-11-10","type":"regulatory","source":"PR Newswire","summary":"Sebela Pharmaceuticals Receives FDA Approval for SUTAB® Tablets for Colonoscopy Preparation - PR Newswire","headline":"Sebela Pharmaceuticals Receives FDA Approval for SUTAB® Tablets for Colonoscopy Preparation","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxOc04yZDA4N1VHUXVoXzF1bVU5ZEk4WWROeW9tZ2Nfa25VbjdWNElCWl9HclU0VEhzVzJvVmd3bFEwbkVHTDZpRE9HUVVhV3RTeUx5cl9QTmJNb09JMVVFdmRZaFptWV96UEJVVk1RM05fLWV0R0lRenZodlJ6RmpDbEt6d2pvNWdu?oc=5","date":"2020-11-04","type":"pipeline","source":"DCAT Value Chain Insights","summary":"Solid-Dosage Mfg: CDMO Market and Product Trends - DCAT Value Chain Insights","headline":"Solid-Dosage Mfg: CDMO Market and Product Trends","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}